The Efficacy of Probiotics in Treatment of Helicobacter
Abstract
BACKGROUND: The standard triple therapy has lost a considerable proportion in it efficiency in treating Helicobacter pylori infection. As such several alternatives and adjuvants have been proposed. One the most promising modulation is the supplementation this therapy with probiotics.
AIMS: This study aimed to investigate the efficiency of probiotic supplementation to traditional triple therapy in the eradication of Helicobacter pylori infection and alleviation of side effects.
PATIENTS AND METHODS: This is a cross-sectional study included 310 consecutive patients newly diagnosed with gastritis or dyspepsia and infected with H. pylori. Patients were randomly divided into three groups based on treatment regimes. Group A: 100 patients received triple therapy consisting of omeprazole, amoxicillin and levofloxacin for two weeks. Group B: 100 patients received tinidazole, levofloxacin and omerprazole for two weeks. Group C: 110 patients received the second protocol plus the probiotic. All patients were reinvestigated four weeks after accomplished treatment by stool antigen test for H. pylori.
RESULTS: The rate of successful H. pylori eradication was 77.74%. In multivariate analysis, each of age≤ 35 years (OR=0.51, 95%CI=0.28-0.93), being married (OR= 0.37, 95%CI=0.21-0.71), never smoker (OR= 0.55, 95%CI=0.32-0.95) and treatment regime with triple therapy supplemented probiotics (OR= 3.36, 95%CI=2.5-21.7) were significantly associated with increased the eradication rate. The…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 310 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.